The NDA submission is based on findings from the Phase III RISE-PD trial of IPX203 for Parkinson’s disease. Credit: Annick Vanblaere from Pixabay.

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Amneal Pharmaceuticals, declining to approve its IPX203 to treat Parkinson’s disease.

The letter was issued in response to a new drug application (NDA) submitted by the company for the therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It stated that while a sufficient scientific bridge has been created for the safety of the ingredient levodopa (LD) in pharmacokinetic studies, this process was insufficiently validated for another ingredient, carbidopa (CD).

The regulatory agency is therefore seeking further data from Amneal.

No problems related to IPX203’s efficacy or production were indicated in the letter.

The company will collaborate with the FDA to discuss these concerns and intends to meet with the regulatory agency to determine a further course of action.

The submission made by Amneal is based on the Phase III RISE-PD clinical trial findings.

According to the trial data, the extended-release dose of IPX203 was demonstrated to provide higher “good on” time and reduced “off” time as against immediate-release CD/LD, even when dosed less often.

Amneal Pharmaceuticals co-CEOs Chirag and Chintu Patel stated: “We are committed to advancing IPX203, which has been developed to provide a longer duration of therapeutic benefit for Parkinson’s disease than existing formulations with fewer doses. 

“We plan to work closely with the FDA to address the agency’s feedback and we remain confident in bringing this new treatment to Parkinson’s patients as soon as possible.”

Last month, the company received approval from the FDA for its 505(b)(2) NDA of Pemrydi RTU, an oncology injectable.